Exec Chat: Myriad CEO Speaks On Defining Its Market And Differentiating Its Offerings
Executive Summary
Myriad CEO Paul Diaz talked to Medtech Insight about how Innovation and investment are two major drivers of differentiation in precision medicine.
You may also be interested in...
Labcorp Buys Myriad Genetics’ Vectra Autoimmune Test Business
Labcorp has agreed to pay $150m in cash for Myriad Genetics’ autoimmune business, one of three major units Myriad is unloading as it tries to narrow its focus to oncology, women's health and mental health diagnostics.
J&J Refines Direction For Ottava
Delays have plagued J&J's soft tissue surgical robot. However, the company has now solidified at least its near-term plan and hopes to commence trials later this year.
J&J Refines Direction For Ottava
Delays have plagued J&J's soft tissue surgical robot. However, the company has now solidified at least its near-term plan and hopes to commence trials later this year.